Pfizer CEO Albert Bourla said the company also plans to submit it’s COVID-19 vaccine to other regulatory authorities around the world.


A third vaccine candidate, this one from AstraZeneca, has shown the capability to be up to 90% effective as pharmaceutical companies around the world race for answers to conquering the pandemic as early as this spring.

Vaccines can’t come soon enough. Since Nov. 12, the United States has reported more coronavirus cases than it did in any full month of the pandemic, while hospitalizations set new highs every day.

The University of Oxford said Monday that it is working with AstraZeneca in submitting interim Phase III data to global regulators for emergency-use approvals. Large scale manufacturing is already underway in more than 10 countries to support “equitable global access,” the university said in a statement.

“The vaccine’s simple supply chain and our no-profit pledge and commitment